Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase IIa study is to determine whether the AD Immunotherapeutic Vaccine
(UB-311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and
immunogenic in mild AD patients. In addition, the efficacy profiles will be evaluated as the
secondary endpoint.